HU0300121A3 - Macrocyclic peptides active against the hepatitis c virus, process for preparation and pharmaceutical compositions containing them - Google Patents

Macrocyclic peptides active against the hepatitis c virus, process for preparation and pharmaceutical compositions containing them

Info

Publication number
HU0300121A3
HU0300121A3 HU0300121A HU0300121A HU0300121A3 HU 0300121 A3 HU0300121 A3 HU 0300121A3 HU 0300121 A HU0300121 A HU 0300121A HU 0300121 A HU0300121 A HU 0300121A HU 0300121 A3 HU0300121 A3 HU 0300121A3
Authority
HU
Hungary
Prior art keywords
hepatitis
virus
preparation
process
pharmaceutical compositions
Prior art date
Application number
HU0300121A
Other versions
HU0300121A2 (en
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12801199P priority Critical
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Priority to PCT/CA2000/000353 priority patent/WO2000059929A1/en
Publication of HU0300121A2 publication Critical patent/HU0300121A2/en
Publication of HU0300121A3 publication Critical patent/HU0300121A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/463The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV]
HU0300121A 1999-04-06 2000-04-03 Macrocyclic peptides active against the hepatitis c virus, process for preparation and pharmaceutical compositions containing them HU0300121A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12801199P true 1999-04-06 1999-04-06
PCT/CA2000/000353 WO2000059929A1 (en) 1999-04-06 2000-04-03 Macrocyclic peptides active against the hepatitis c virus

Publications (2)

Publication Number Publication Date
HU0300121A2 HU0300121A2 (en) 2003-06-28
HU0300121A3 true HU0300121A3 (en) 2004-07-28

Family

ID=22433155

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300121A HU0300121A3 (en) 1999-04-06 2000-04-03 Macrocyclic peptides active against the hepatitis c virus, process for preparation and pharmaceutical compositions containing them

Country Status (34)

Country Link
EP (2) EP1437362A1 (en)
JP (1) JP3754298B2 (en)
CN (2) CN1618789A (en)
AR (1) AR023260A1 (en)
AT (1) AT277945T (en)
AU (1) AU778390B2 (en)
BG (1) BG65356B1 (en)
BR (1) BR0009599A (en)
CA (1) CA2367127C (en)
CO (1) CO5170502A1 (en)
CZ (1) CZ20013467A3 (en)
DE (1) DE60014345T2 (en)
DK (1) DK1169339T3 (en)
EE (1) EE04816B1 (en)
ES (1) ES2230084T3 (en)
HK (1) HK1042714A1 (en)
HR (1) HRP20010720A2 (en)
HU (1) HU0300121A3 (en)
ID (1) ID30459A (en)
IL (2) IL145375D0 (en)
MX (1) MXPA01010090A (en)
NO (1) NO20014857L (en)
NZ (1) NZ515286A (en)
PE (1) PE20001649A1 (en)
PL (1) PL350855A1 (en)
PT (1) PT1169339E (en)
RU (1) RU2247126C2 (en)
SI (1) SI1169339T1 (en)
SK (1) SK14072001A3 (en)
TR (1) TR200102878T2 (en)
UA (1) UA74546C2 (en)
WO (1) WO2000059929A1 (en)
YU (1) YU70701A (en)
ZA (1) ZA200107862B (en)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229997B1 (en) 2000-07-21 2015-04-28 Dendreon Corp San Diego Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2002243600B2 (en) 2001-01-22 2006-09-28 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003223602B8 (en) 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
JP4312711B2 (en) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Heterocyclic sulfonamide hepatitis C virus inhibitor
MY140680A (en) 2002-05-20 2010-01-15 Squibb Bristol Myers Co Hepatitis c virus inhibitors
US7041698B2 (en) 2002-05-20 2006-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US6878722B2 (en) 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
US20040138109A1 (en) * 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
EP1408031A1 (en) * 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ES2298585T3 (en) * 2002-10-29 2008-05-16 Boehringer Ingelheim International Gmbh Ns3 hcv proteasa inhibitors resistant.
US20050159345A1 (en) * 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (en) * 2003-02-07 2006-05-10 益安药业 Macrocyclic hepatitis c serine protease inhibitors
UY28240A1 (en) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma crystalline phases of a potent inhibitor hcv
EP1613353A1 (en) 2003-04-02 2006-01-11 Boehringer Ingelheim International GmbH Pharmaceutical compositions for hepatitis c viral protease inhibitors
WO2004089974A1 (en) * 2003-04-10 2004-10-21 Boehringer Ingelheim International Gmbh Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
EP1615947A2 (en) 2003-04-10 2006-01-18 Boehringer Ingelheim International GmbH Process for preparing macrocyclic compounds
EP1629000B1 (en) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
DK1615613T3 (en) 2003-04-18 2010-03-22 Enanta Pharm Inc Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
BRPI0410456B1 (en) 2003-05-21 2019-07-09 Boehringer Ingelheim International Gmbh Hepatitis c inhibitors, pharmaceutical composition, use thereof, as a manufacturing article
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005028501A1 (en) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
JP4525982B2 (en) * 2003-09-26 2010-08-18 シェーリング コーポレイションSchering Corporation Macrocyclic inhibitor of NS3 serine protease of hepatitis C virus
KR20060130027A (en) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2004281780B2 (en) 2003-10-14 2009-03-19 F. Hoffmann-La Roche Ltd Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
KR20060120166A (en) 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Hcv ns3-ns4a protease resistance mutants
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007516239A (en) 2003-11-20 2007-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for removing transition metals, particularly from metathesis products
CN1902216A (en) * 2003-11-20 2007-01-24 先灵公司 Depeptidized inhibitors of hepatitis c virus NS3 protease
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007513200A (en) * 2003-12-08 2007-05-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Removal of ruthenium by-products by supercritical fluid treatment
JP4682155B2 (en) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Macrocyclic peptide active against hepatitis C virus
WO2005075502A1 (en) * 2004-01-28 2005-08-18 Boehringer Ingelheim International Gmbh Method of removing transition metals from reaction solutions comprising transition metal byproducts
ES2336009T3 (en) * 2004-01-30 2010-04-07 Medivir Ab Inhibitors of the ns-3 serina proteasa hcv.
AU2011203349B2 (en) * 2004-01-30 2012-05-24 Medivir Ab HCV NS-3 serine protease inhibitors
US7683033B2 (en) 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN103333162A (en) 2004-02-20 2013-10-02 贝林格尔.英格海姆国际有限公司 Viral polymerase inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
CA2557307A1 (en) 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
AU2005222055A1 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
CA2557322A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
CA2557301A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
KR20060124729A (en) 2004-02-27 2006-12-05 쉐링 코포레이션 Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
BRPI0508867A (en) 2004-03-15 2007-09-04 Boehringer Ingelheim Int process for the preparation of macrocyclic compounds
NZ549697A (en) * 2004-03-30 2009-12-24 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
CN1984922A (en) 2004-05-20 2007-06-20 先灵公司 Substituted prolines as inhibitors of hepatitis c virus NS3 serine protease
EP1758453B1 (en) 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2006012078A2 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
AP2461A (en) * 2004-07-16 2012-09-14 Gilead Sciences Inc Antiviral compounds
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogs of dipeptide inhibitors of hepatitis c
EP1771454B1 (en) 2004-07-20 2011-06-15 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
US7550559B2 (en) 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2006033878A1 (en) * 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic hcv protease inhibitors
EP1794179A1 (en) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
AT533473T (en) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma New class of surfuctant-like materials with vitamin-e-tpgs and water-soluble polymer
EP1805187A1 (en) * 2004-10-21 2007-07-11 Pfizer, Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
DE602005026222D1 (en) 2004-12-20 2011-03-17 Codman & Shurtleff Hcv inhibitor for use in a method for the treatment of hepatitis c
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
DE102005002336A1 (en) 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for conducting continuous olefin-ring closure metathesis in compressed carbon dioxide
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101160317B (en) 2005-03-08 2013-03-27 贝林格尔·英格海姆国际有限公司 Process for preparing macrocyclic compounds
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5030947B2 (en) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド Compounds and methods for the treatment and prevention of flavivirus infections
WO2006130666A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
CA2610167A1 (en) 2005-06-02 2006-12-07 Schering Corporation Administration of hcv protease inhibitors in combination with food to improve bioavailability
MX2007015270A (en) 2005-06-02 2008-02-21 Schering Corp Combination of hcv protease inhibitors with a surfactant.
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
AU2006276246B2 (en) 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
ME01318B (en) 2005-07-29 2013-12-20 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
US8183277B2 (en) 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
RU2437886C2 (en) 2005-07-29 2011-12-27 Тиботек Фармасьютикалз Лтд. Macrocyclic hepatitis c virus inihbitors
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Macrocylic Inhibitors Hepatitis C Virus
PE20070211A1 (en) * 2005-07-29 2007-05-12 Medivir Ab Macrocyclic compounds as inhibitors of hepatitis C virus
EA014293B1 (en) 2005-07-29 2010-10-29 Тиботек Фармасьютикалз Лтд. Macrocyclic inhibitors of hepatitus c virus
PE20070343A1 (en) * 2005-07-29 2007-05-12 Medivir Ab Macrocyclic inhibitors of the Hepatitis C virus
PE20070210A1 (en) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Macrocyclic compounds as inhibitors of hepatitis C virus
AR055105A1 (en) 2005-07-29 2007-08-08 Tibotec Pharm Ltd Macrocyclic inhibitors of the Hepatitis C virus
ES2360417T3 (en) * 2005-07-29 2011-06-03 Medivir Ab Macrocyclic inhibitors of hepatitis virus c.
AR057703A1 (en) * 2005-07-29 2007-12-12 Tibotec Pharm Ltd INHIBITORS macrocyclic HEPATITIS VIRUS C. PROCESS preparation and pharmaceutical compositions.
RU2008107972A (en) 2005-08-01 2009-09-10 Мерк энд Ко., Инк. (US) Macrocyclic peptides as hcv ns3-protease inhibitors
JP2009505966A (en) 2005-08-02 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Inhibitor of serine protease
AU2006280175B2 (en) 2005-08-09 2011-09-01 Merck Sharp & Dohme Corp. Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2357170A1 (en) 2005-08-19 2011-08-17 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma Inhibiting compounds serine protease activity of NS3-NS4A the Hepatitis C virus
NZ568135A (en) 2005-10-11 2011-06-30 Array Biopharma Inc Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008123606A (en) 2005-11-11 2009-12-20 Вертекс Фармасьютикалз, Инк (Us) Hepatitis C Virus Options
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
PE20080992A1 (en) * 2006-06-26 2008-08-06 Enanta Pharm Inc Quinoxalinyl macrocyclic inhibitors of the serine protease Hepatitis C virus
KR20090024834A (en) 2006-07-05 2009-03-09 어레이 바이오파마 인크. Novel inhibitors of hepatitis c virus replication
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2008008502A1 (en) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2054388A4 (en) 2006-08-17 2009-10-28 Boehringer Ingelheim Int Viral polymerase inhibitors
JP5345541B2 (en) 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. HCV NS3 protease inhibitor
WO2008051514A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP2010507656A (en) 2006-10-24 2010-03-11 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー HCV NS3 protease inhibitor
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
NZ576345A (en) 2006-10-27 2011-11-25 Angeletti P Ist Richerche Bio Hcv ns3 protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201101492A1 (en) 2006-11-15 2012-09-28 Вирокем Фарма Инк. Tiophene analogues for the treatment or prevention of flavivirus infections
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI406660B (en) 2006-11-17 2013-09-01 Tibotec Pharm Ltd Macrocyclic inhibitors of hepatitis c virus
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (en) 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Antiviral indole
BRPI0806853B1 (en) * 2007-02-01 2018-03-20 Janssen Sciences Ireland Uc Processes and intermediaries to prepare an hcv macrocyclic protease inhibitor
RU2481340C2 (en) * 2007-02-08 2013-05-10 Тиботек Фармасьютикалз Лтд. Pyrimidine substituted macrocyclic hcv inhibitors
KR20090111326A (en) * 2007-02-08 2009-10-26 메디비르 아베 Hcv inhibiting macrocyclic phenylcarbamates
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
JP2010526143A (en) 2007-05-04 2010-07-29 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
KR20100027134A (en) 2007-05-10 2010-03-10 어레이 바이오파마 인크. Novel peptide inhibitors of hepatitis c virus replication
AU2008271117B2 (en) 2007-06-29 2013-10-24 Gilead Sciences, Inc. Antiviral compounds
KR20150006905A (en) * 2007-06-29 2015-01-19 길리애드 사이언시즈, 인코포레이티드 Antiviral compound
EP2178886A1 (en) 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic indole derivatives for the treatment of hepatitis c infections
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
JP2010535156A (en) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Viral polymerase inhibitor
JP2012520884A (en) 2009-03-18 2012-09-10 アイガー バイオファーマシューティカルズ インコーポレイテッド Methods and compositions for treating flaviviridae viral infections
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8940688B2 (en) 2007-12-05 2015-01-27 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide HCV serine protease inhibitors
CA2708047A1 (en) 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors
MX2010006313A (en) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Viral polymerase inhibitors.
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8003659B2 (en) 2008-02-04 2011-08-23 Indenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
MX2010011306A (en) 2008-04-15 2010-11-09 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2009148923A1 (en) * 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA019327B1 (en) 2008-07-22 2014-02-28 Мерк Шарп Энд Домэ Корп. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc Serine protease inhibitors macrocyclic hepatitis c
PE20130307A1 (en) 2008-09-16 2013-03-22 Boehringer Ingelheim Int Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy, a potent inhibitor of hcv
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
US8445430B2 (en) 2008-11-20 2013-05-21 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
CA2746265A1 (en) * 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
CN102245599B (en) 2008-12-10 2014-05-14 艾其林医药公司 New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012514605A (en) 2009-01-07 2012-06-28 サイネクシス,インコーポレーテッド Cyclosporine derivatives for use in the treatment of HCV and HIV infection
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
AR075584A1 (en) 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS COMPRISING beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine ACID AND DERIVATIVE isoindole carboxylic acid and its uses. COMPOUND.
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CN102458444A (en) 2009-05-13 2012-05-16 英安塔制药有限公司 Macrocyclic compounds as hepatitis c virus inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
EP2504343A4 (en) * 2009-11-24 2013-04-17 Boehringer Ingelheim Int Hepatitis c inhibitor compounds
WO2011063502A1 (en) * 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
MX2012006026A (en) 2009-11-25 2012-08-15 Vertex Pharma 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections.
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
AU2010336355A1 (en) 2009-12-24 2012-07-05 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP2013522377A (en) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Analogs for treating or preventing flavivirus infection
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
CN102869657A (en) 2010-03-24 2013-01-09 沃泰克斯药物股份有限公司 Analogues for the treatment or prevention of flavivirus infections
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
ES2628418T3 (en) * 2010-05-20 2017-08-02 Array Biopharma, Inc. Macrocyclic compounds as inhibitors of TRK kinase
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
CN103153978A (en) 2010-08-17 2013-06-12 沃泰克斯药物股份有限公司 Compounds and methods for the treatment or prevention of flaviviridae viral infections
BR112013006693A2 (en) 2010-09-21 2016-06-14 Enanta Pharm Inc macrocyclic proline derived hcv serine protease inhibitors
EA201390988A1 (en) * 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Phenantridine macrocyclic inhibitors of the hypatitis c virus serin protease
MX2013007677A (en) 2010-12-30 2013-07-30 Abbvie Inc Macrocyclic hepatitis c serine protease inhibitors.
TW201309690A (en) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201317223A (en) 2011-07-26 2013-05-01 Vertex Pharma Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
SG11201402899TA (en) 2011-12-06 2014-07-30 Univ Leland Stanford Junior Methods and compositions for treating viral diseases
KR20140114827A (en) 2012-01-11 2014-09-29 에프. 호프만-라 로슈 아게 Macrocyclic amides as protease inhibitors
US20140356325A1 (en) 2012-01-12 2014-12-04 Ligand Pharmaceuticals Incorporated Novel 2'-c-methyl nucleoside derivative compounds
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
SI2909205T1 (en) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) * 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
SG11201908863VA (en) * 2017-03-24 2019-10-30 Agency Science Tech & Res Building blocks for stapled peptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5500208A (en) * 1994-06-07 1996-03-19 The Procter & Gamble Company Oral compositions comprising a novel tripeptide
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
WO1997043310A1 (en) * 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
ZA9709327B (en) * 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
GB9707659D0 (en) * 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
NZ503262A (en) * 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
CA2294562C (en) * 1997-08-11 2005-07-26 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
EP1066247B1 (en) * 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (en) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptide inhibitors of hepatitis c, a pharmaceutical composition containing them, the use thereof for preparing a pharmaceutical composition, the use of an intermediate for the preparation of these peptides and a process for the preparation of a peptide analogue thereof .
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides

Also Published As

Publication number Publication date
AU778390B2 (en) 2004-12-02
YU70701A (en) 2005-07-19
BR0009599A (en) 2002-01-15
EP1169339B1 (en) 2004-09-29
DE60014345T2 (en) 2005-02-17
MXPA01010090A (en) 2002-04-24
PL350855A1 (en) 2003-02-10
HRP20010720A2 (en) 2002-12-31
TR200102878T2 (en) 2002-01-21
ID30459A (en) 2001-12-06
NZ515286A (en) 2004-02-27
DK1169339T3 (en) 2005-01-10
SI1169339T1 (en) 2005-02-28
NO20014857D0 (en) 2001-10-05
JP2002542160A (en) 2002-12-10
CN1618789A (en) 2005-05-25
CA2367127C (en) 2005-01-18
PT1169339E (en) 2004-12-31
BG65356B1 (en) 2008-03-31
WO2000059929A1 (en) 2000-10-12
CZ20013467A3 (en) 2002-06-12
ES2230084T3 (en) 2005-05-01
CN1177861C (en) 2004-12-01
IL145375D0 (en) 2002-06-30
UA74546C2 (en) 2002-02-15
EP1169339A1 (en) 2002-01-09
ZA200107862B (en) 2004-06-30
CO5170502A1 (en) 2002-06-27
CN1346365A (en) 2002-04-24
CA2367127A1 (en) 2000-10-12
EE200100516A (en) 2002-12-16
PE20001649A1 (en) 2001-02-06
IL145375A (en) 2007-05-15
RU2247126C2 (en) 2005-02-27
HU0300121A2 (en) 2003-06-28
AU3548000A (en) 2000-10-23
AT277945T (en) 2004-10-15
JP3754298B2 (en) 2006-03-08
BG105970A (en) 2002-05-31
EP1437362A1 (en) 2004-07-14
NO20014857L (en) 2001-10-31
DE60014345D1 (en) 2004-11-04
AR023260A1 (en) 2002-09-04
HK1042714A1 (en) 2005-04-01
SK14072001A3 (en) 2002-03-05
EE04816B1 (en) 2007-04-16

Similar Documents

Publication Publication Date Title
DE60001190D1 (en) Aminotriazole compounds, processes for their preparation and pharmaceutical compositions containing them
DZ3311A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
DE60030429D1 (en) Neuronals, the exocytosis-inhibiting peptides and these cosmetic and pharmaceutical compositions containing
IL145071D0 (en) Fused ring compounds and pharmaceutical compositions containing the same
IL151685D0 (en) Polyglutamic acid-camptothecin conjugates, methods for the preparation thereof and pharmaceutical compositons containing the same
IL144626A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
IL140552D0 (en) Linear cyclodextrin copolymers, pharmaceutical compositions containing the same and methods for the preparation thereof
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
IL174403D0 (en) Macrocyclic peptides active against the hepatitis c virus
HU0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
GB9307527D0 (en) New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
HU0303524A3 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use
ZA9808585B (en) Pharmaceutical compositions containing plasma protein.
ZA9811759B (en) Novel indole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them.
HU227841B1 (en) 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
IL108873D0 (en) 2-debenzoyl-2-acyl taxol derivatives, pharmaceutical compositions containing the same, and methods for the preparation thereof
ZA200103204B (en) Novel amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same.
BR9810802B1 (en) compound, pharmaceutical composition, and process for the preparation of a compound.
IL128601D0 (en) 7alpha-(epsilon-aminoalkyl) estratrienes, process for preparing the same, pharmaceutical preparation containing said 7alpha-(epsilon-aminoalkyl) estratrienes and their use for preparing medicaments
HU0105136A3 (en) Amide derivatives, process for their preparation and medicaments containing them
AU8592591A (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
DE50013167D1 (en) 2'-substituted 1,1'-biphenyl-2-carboxamides, method for the production thereof, their use as medicament and pharmaceutical preparations containing they
HU0103082A3 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
HU0204519A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations
HU0300207A3 (en) 1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees